The safety of adalimumab was much like that of infliximab
The safety of adalimumab was much like that of infliximab. Primary data from open-label studies showed efficacy of adalimumab in mild-to-moderate UC with lack of response or poor tolerability to infliximab [Trinder and Lawrance, 2009, Peyrin-Biroulet 2005]. in america. Vedolizumab (MLN0002), an anti-47 integrin antibody, includes a great safety and efficiency profile. Monoclonal antibodies targeting…